Formulation of amphotericin B as nanosuspension for oral administration

Kayser, O; Olbrich, C; Yardley, V; Kiderlen, AF; Croft, SL; (2003) Formulation of amphotericin B as nanosuspension for oral administration. International journal of pharmaceutics, 254 (1). pp. 73-75. ISSN 0378-5173 DOI:

Full text not available from this repository. (Request a copy)


Amphotherin B was formulated in a nanosuspension as a new oral drug delivery system for the treatment of experimental visceral leishmaniasis. Amphotericin B (AmB) nanosuspensions were produced by high pressure homogenisation obtaining particles with a PCs diameter of 528 nm. Environmental stability was determined in artificial gastrointestinal fluids at different pH and electrolyte concentrations. In vivo efficacy was determined in a mouse model of visceral leishmaniasis. Following oral administration (5 mg kg(-1)), micronised amphotericin B did not show any curative effect. However, administrations of amphotericin B nanosuspension, reduced liver parasite load by 28.6% compared to untreated controls. (C) 2002 Elsevier Science B.V. All rights reserved.

Item Type: Article
Keywords: amphotericin, Leishmania, nanosuspension, oral
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Immunology and Infection
Research Centre: Leishmaniasis Group
PubMed ID: 12615413
Web of Science ID: 181727800016


Download activity - last 12 months
Downloads since deposit
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item